What is the usage and dosage of Revumenib-Revuforj?

Revumenib (Revumenib)-Revuforj usage and dosage vary depending on the patient's age, weight, and concomitant use of strong CYP3A4 inhibitors. As a targeted drug that needs to be taken orally for a long time, its dosage setting must not only ensure efficacy but also avoid excessive toxicity.

In the pediatric population, the application scope of Revimenib covers children aged 1 year and above. For children weighing less than 40 kg and not taking a strong CYP3A4 inhibitor concomitantly, the recommended dose is 160 mg/m2 twice daily; if a strong CYP3A4 inhibitor is being taken, the dose should be adjusted to 95 mg/m2 twice a day. For children weighing 40 kg or more, if a strong CYP3A4 inhibitor is not used, the recommended dose is 270 mg twice daily; if a CYP3A4 inhibitor is used concomitantly, the recommended dose should be reduced to 160 mg twice daily.

In adult patients, dosage settings are similar to those in children. For adults weighing less than 40 kg who are not using a CYP3A4 inhibitor, the recommended dose is 160 mg twice daily; if a CYP3A4 inhibitor is being used, the recommended dose is 95 mg/m2 twice daily. Adults weighing 40 kg and above, if not taking a CYP3A4 inhibitor concomitantly, take 270 mg twice a day; if taking a CYP3A4 inhibitor concomitantly, adjust to 160 mg twice a day.

In general, treatment with revimenib should be continued until disease progression or unacceptable toxicity occurs. In most cases, doctors will recommend continuous treatment for at least 6 months to fully observe clinical response. If the patient experiences severe side effects, the dose needs to be adjusted based on clinical manifestations or treatment should be suspended. In addition, because revemenib is mainly metabolized by the liver, patients should avoid using other drugs that affect the CYP3A4 pathway at the same time during medication to avoid abnormal blood drug concentrations.

Reference materials:https://www.drugs.com/monograph/revumenib.html